Treatment
Treatment
09/19/2017
Researchers determined the feasibility and benefits of switching from PDE5i therapy to riociguat in patients with PAH who fail PDE5i therapy.
09/19/2017
FDA
FDA
09/07/2017
The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
09/07/2017
drug treatment
drug treatment
05/19/2017
A recent study investigated pharmacokinetic interactions between phosphodiesterase type 5 inhibitors and endothelin receptor antagonists used in combination for the treatment of pulmonary arterial...
05/19/2017
Pulmonology
Pulmonology
05/05/2017
Pulmonary arterial hypertension can be associated with exposure to certain drugs, such as anorectic agents or selective serotonin reuptake inhibitors.
05/05/2017
Pulmonology
Pulmonology
05/02/2017
Ambrisentan may be an effective adjunctive therapy for patients with pulmonary arterial hypertension who inadequately respond to PDE5i monotherapy.
05/02/2017
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
05/01/2017
Researchers sought to determine if any serological biomarkers for PAH could be identified in patients with systemic lupus erythematosus.
05/01/2017
Magnetic resonance imaging
Magnetic resonance imaging
04/26/2017
A recent study evaluated the efficacy of magnetic resonance imaging measurements for assessing potential outcomes in patients with pulmonary arterial hypertension.
04/26/2017
Blood Pressure
Blood Pressure
06/10/2016
The relationship between elevated plasma endothelin-1 levels and pulmonary hypertension, mortality, and heart failure was assessed in a recent study.
06/10/2016